08:10 AM EDT, 10/27/2025 (MT Newswires) -- Zenas BioPharma ( ZBIO ) said Monday that a phase 2 trial of obexelimab in relapsing multiple sclerosis achieved its primary endpoint, with a 95% reduction in new gadolinium-enhancing T1 hyperintense lesions compared with placebo.

The "near-complete suppression" of gadolinium-enhancing T1 hyperintense lesions, which are markers of active inflammation, was observed by week 8 and sustained through week 12, the company said.

Obexelimab's safety profile in the phase 2 trial was consistent with previously completed trials, Zenas said, adding it expects to report the trial's week 24 data in Q1 2026.

The company also said it expects to report topline results from a phase 3 trial of obexelimab in chronic inflammatory condition IgG4-RD around the end of 2025 and topline results from a phase 2 trial in systemic lupus erythematosus in mid-2026.

Shares of Zenas BioPharma ( ZBIO ) were up more than 22% in recent premarket activity Monday.